NCT04940767View on ClinicalTrials.gov

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Acne Vulgaris
Interventions
DRUG

Isotretinoin

Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.

DRUG

Amzeeq 4% Topical Foam

AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019

Trial Locations (2)

78620

Austin Institute for Clinical Research, Inc., Dripping Springs

78660

Austin Institute for Clinical Research, Inc., Pflugerville

All Listed Sponsors
collaborator

Vyne Therapeutics Inc.

INDUSTRY

lead

Edward Lain, MD

NETWORK